The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow-Reference-Cited by-同舟云学术

The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow

Published:2018-01-05 Issue:1 Volume:13 Page:e0190525
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Lange Andrzej^ORCID,Jaskula Emilia,Lange Janusz,Dworacki Grzegorz,Nowak Dorota,Simiczyjew Aleksandra,Mordak-Domagala Monika,Sedzimirska Mariola

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference34 articles.

1. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade;T Badar;Am J Hematol,2015

2. Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia;N Ramos;J Clin Med,2015

3. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer;S Wilhelm;Nat Rev Drug Discov,2006

4. Potential role of sorafenib in the treatment of acute myeloid leukemia;S Mori;Leuk Lymphoma,2008

5. Sorafenib–a small molecule with big promise?;T Tadmor;Leuk Lymphoma,2010

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect;Frontiers in Immunology;2024-03-20

2. Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours;Expert Review of Hematology;2022-11-02

3. Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia;International Journal of Molecular Sciences;2022-10-21

4. Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure;Cancers;2022-09-02

5. Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy;Transplantation and Cellular Therapy;2022-09